Insight, China's Pharmaceutical Industry

Company Deals

Pfizer Licenses Chai Discovery’s AI Platform for Drug Discovery – Gains Early Access to Breakthrough Chai-3 Model for Antibody Design

Pfizer (NYSE: PFE) announced a strategic license agreement with Chai Discovery, an artificial intelligence company...

Company Drug

Biogen Secures FDA Breakthrough Therapy Designation for Salanersen in Spinal Muscular Atrophy – Once-Yearly ASO with Novel Chemical Structure

Fineline Cube Jun 5, 2026

Biogen (NASDAQ: BIIB) announced it has received Breakthrough Therapy Designation (BTD) from the U.S. Food...

Company Drug

Innovent Biologics Reports Positive Phase III Results for IBI343 in Advanced Gastric Cancer – CLDN18.2-Targeting ADC Files NDA with NMPA

Fineline Cube Jun 5, 2026

Innovent Biologics (HKG: 1801) announced that the pre-specified first interim analysis from the global Phase...

Company Deals

Everest Medicines Secures Asia-Pacific Rights to Mabworks’ Obexelimab β in $30.9M Deal – First-in-Class CD20 Antibody for NMOSD

Fineline Cube Jun 5, 2026

Everest Medicines (HKG: 1952) announced a licensing agreement with fellow Chinese biopharmaceutical company Beijing Mabworks...

Company Drug

Jiangsu Vcare PharmaTech Secures NMPA Approval for Eratrectinib – Next-Generation TRK Inhibitor with Enhanced Brain Penetration and Circular Molecular Structure

Fineline Cube Jun 5, 2026

Jiangsu Vcare PharmaTech Co., Ltd. announced that China’s National Medical Products Administration (NMPA) has granted...

Company Medical Device

GE HealthCare Secures FDA 510(k) Clearance for MIM Contour ProtégéAI+ 2.0 – AI Auto-Contouring Platform with Predetermined Change Control Plan

Fineline Cube Jun 5, 2026

GE HealthCare (NASDAQ: GEHC) announced it has received 510(k) clearance from the United States Food...

Company Drug

Hansoh Pharmaceutical’s Olatorepatide GLP-1/GIP Dual Agonist Accepted for NMPA Review for Weight Management Indication

Fineline Cube Jun 4, 2026

Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced that China’s National Medical Products Administration (NMPA)...

Company Drug

Johnson & Johnson’s Nipocalimab (Imaavy) Demonstrates Efficacy in Phase II JASMINE Study for Systemic Lupus Erythematosus, First FcRn Blocker to Show Success in SLE

Fineline Cube Jun 4, 2026

Johnson & Johnson (J&J, NYSE: JNJ) announced positive results from the Phase II JASMINE study...

Company Deals

Lundbeck Partners with Cradle to Deploy AI-Guided Protein Engineering for CNS Antibody Discovery

Fineline Cube Jun 4, 2026

H. Lundbeck A/S (OTCMKTS: HLUBF) announced on June 3, 2026, a strategic partnership with Cradle,...

Company Drug

Novo Nordisk Launches Wegovy Oral Tablets in UAE – First International Market Outside US for Semaglutide Weight Management Therapy

Fineline Cube Jun 4, 2026

Novo Nordisk A/S (NYSE: NVO) announced the market launch of Wegovy (semaglutide) oral tablets in...

Company Deals Medical Device

Medtronic Makes Strategic ICE Catheter Investments to Strengthen Cardiac Ablation Leadership and Affera Ecosystem Integration

Fineline Cube Jun 4, 2026

Medtronic plc (NYSE: MDT) announced on June 3, 2026, strategic investments in two privately held...

Company Deals

Regeneron Expands CytomX Partnership to $4 Billion in Potential Milestones for Conditionally-Activated Bispecific Cancer Therapies

Fineline Cube Jun 4, 2026

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has significantly expanded its collaboration with fellow US biotechnology company...

Company Deals

Ascidian Therapeutics Partners with Eli Lilly in $1.9 Billion RNA Exon Editing Deal for Monogenic Kidney Diseases

Fineline Cube Jun 4, 2026

Ascidian Therapeutics, a US-based biotechnology company pioneering RNA exon editing technology, announced a global research...

Company Medical Device

Medtronic Submits FDA 510(k) Filings to Expand Hugo RAS System into General and Gynecologic Surgery, Adds LigaSure Maryland Instrument

Fineline Cube Jun 4, 2026

Medtronic plc (NYSE: MDT) announced on June 3, 2026, the submission of 510(k) premarket notifications...

Company Drug

Yunnan Baiyao Secures FDA Clinical Approval for INB301 in Tumor Cachexia – First Chinese TCM Company to Advance Novel Therapy in US Oncology Market

Fineline Cube Jun 4, 2026

Yunnan Baiyao Group Co., Ltd. (SHE: 000538), a leading traditional Chinese medicine (TCM) company, announced...

Company Drug

Changchun High & New Tech Secures NMPA Clinical Trial Approval for GenSci155 in Dual Indications: Bronchopulmonary Dysplasia and Acute Ischemic Stroke

Fineline Cube Jun 4, 2026

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced it has received clinical...

Company

Medtronic Reports Strong Q4 and FY26 Results with 6.6% Organic Growth, Cardiac Ablation Solutions Surge 78%

Fineline Cube Jun 4, 2026

Medtronic plc (NYSE: MDT) announced financial results for its fourth quarter (Q4) and fiscal year...

Policy / Regulatory

FDA Issues Draft Guidance to Accelerate Gene Therapy Development Through Platform Knowledge Sharing

Fineline Cube Jun 4, 2026

The U.S. Food and Drug Administration (FDA) released draft guidance on June 2, 2026, designed...

Policy / Regulatory

China’s National Health Commission Unveils Ambitious Plan for Community Health Service Expansion by 2030

Fineline Cube Jun 4, 2026

China’s National Health Commission (NHC) has released the “Notice on Further Improving the Urban Community...

Company Deals

Shandong Boan Biotech Licenses BA5101 Dulaglutide Biosimilar for US Market – First Global Copycat of Trulicity

Fineline Cube Jun 4, 2026

Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced a licensing agreement with an undisclosed pharmaceutical...

Insight, China's Pharmaceutical Industry

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Insilico Medicine and THPharma Launch AI Research Collaboration to Build ‘Reverse Translation’ Drug Discovery Strategy Around Phase 3 Candidate THP-001

Zhaoke Ophthalmology Signs Exclusive Distribution and Promotion Agreement With Pengpai Bio for Epinastine Hydrochloride Eye Drops in Mainland China

Allist Pharmaceuticals Secures Exclusive Greater China License for ArriVent’s Bispecific ADC AST12608/ARR-002

Kintor Pharmaceutical Grants Wellrise Exclusive Distribution Rights for KT-939 Raw Material in South Korea

Ark Biopharmaceutical’s First-in-Class AFC AK0406 Wins NMPA Approval for Influenza Prevention Clinical Trials

Youcare Pharmaceutical’s YKYY033 siRNA Injection Wins US FDA Approval to Conduct Clinical Trials for Arterial and Venous Thrombosis

Pfizer Licenses Chai Discovery’s AI Platform for Drug Discovery – Gains Early Access to Breakthrough Chai-3 Model for Antibody Design

Biogen Secures FDA Breakthrough Therapy Designation for Salanersen in Spinal Muscular Atrophy – Once-Yearly ASO with Novel Chemical Structure

Innovent Biologics Reports Positive Phase III Results for IBI343 in Advanced Gastric Cancer – CLDN18.2-Targeting ADC Files NDA with NMPA

Everest Medicines Secures Asia-Pacific Rights to Mabworks’ Obexelimab β in $30.9M Deal – First-in-Class CD20 Antibody for NMOSD

Jiangsu Vcare PharmaTech Secures NMPA Approval for Eratrectinib – Next-Generation TRK Inhibitor with Enhanced Brain Penetration and Circular Molecular Structure

GE HealthCare Secures FDA 510(k) Clearance for MIM Contour ProtégéAI+ 2.0 – AI Auto-Contouring Platform with Predetermined Change Control Plan

Hansoh Pharmaceutical’s Olatorepatide GLP-1/GIP Dual Agonist Accepted for NMPA Review for Weight Management Indication

Johnson & Johnson’s Nipocalimab (Imaavy) Demonstrates Efficacy in Phase II JASMINE Study for Systemic Lupus Erythematosus, First FcRn Blocker to Show Success in SLE

Lundbeck Partners with Cradle to Deploy AI-Guided Protein Engineering for CNS Antibody Discovery

Novo Nordisk Launches Wegovy Oral Tablets in UAE – First International Market Outside US for Semaglutide Weight Management Therapy

Medtronic Makes Strategic ICE Catheter Investments to Strengthen Cardiac Ablation Leadership and Affera Ecosystem Integration

Regeneron Expands CytomX Partnership to $4 Billion in Potential Milestones for Conditionally-Activated Bispecific Cancer Therapies

Ascidian Therapeutics Partners with Eli Lilly in $1.9 Billion RNA Exon Editing Deal for Monogenic Kidney Diseases

Medtronic Submits FDA 510(k) Filings to Expand Hugo RAS System into General and Gynecologic Surgery, Adds LigaSure Maryland Instrument

Yunnan Baiyao Secures FDA Clinical Approval for INB301 in Tumor Cachexia – First Chinese TCM Company to Advance Novel Therapy in US Oncology Market

Changchun High & New Tech Secures NMPA Clinical Trial Approval for GenSci155 in Dual Indications: Bronchopulmonary Dysplasia and Acute Ischemic Stroke

Medtronic Reports Strong Q4 and FY26 Results with 6.6% Organic Growth, Cardiac Ablation Solutions Surge 78%

FDA Issues Draft Guidance to Accelerate Gene Therapy Development Through Platform Knowledge Sharing

China’s National Health Commission Unveils Ambitious Plan for Community Health Service Expansion by 2030

Shandong Boan Biotech Licenses BA5101 Dulaglutide Biosimilar for US Market – First Global Copycat of Trulicity

You Missed

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Insilico Medicine and THPharma Launch AI Research Collaboration to Build ‘Reverse Translation’ Drug Discovery Strategy Around Phase 3 Candidate THP-001

Ark Biopharmaceutical’s First-in-Class AFC AK0406 Wins NMPA Approval for Influenza Prevention Clinical Trials

Youcare Pharmaceutical’s YKYY033 siRNA Injection Wins US FDA Approval to Conduct Clinical Trials for Arterial and Venous Thrombosis